摘要
目的探讨拓扑异构酶Ⅱa【（TopoⅡa）和环氧合酶-2（COX-2）在乳腺癌组织中的表达及其与临床病理特征的关系。方法采用免疫组织化学法检测50例乳腺癌组织中TopoⅡa和COX-2的表达。结果TopoⅡa在乳腺癌及其周围正常乳腺组织中表达率分别为64％（32／50）和22％（11／50）；COX-2在乳腺癌及其周围正常乳腺组织中表达率分别为68％（34／50）和14％（7／50），差异均有统计学意义（P〈0．05）。TopⅡa的表达仅与乳腺癌组织学分级有关（P〈0．05），而与患者年龄、肿瘤大小、淋巴结转移和临床分期无关（P〉0．05）；COX-2表达与肿瘤大小、组织学分级、淋巴结转移和临床分期有关（P〈0．05），而与患者年龄无关（P〉0．05）。结论TopoⅡa和COX-2的检测可作为评价乳腺癌分化程度和侵袭、转移的指标。
Objective To explore the expression of Topo Ⅱa and COX-2 in breast cancer tissues and investigate their correlations to clinicopathologic feature of breast cancer. Methods The expression of Topo Ⅱa and COX-2 in 50 specimens of breast cancer and their normal tissues were detected by immunohistochemistry. Their correlation to clinicopathologic features of breast cancer were analyzed. Results The positive rates of Topo Ⅱa were 64 % （32/50） and 22 % （11/50） and COX-2 were 68 % （34/50） , 14 % （7/50） in breast cancer and normal tissue （P〈0.05）. The expression of Topo Ⅱa was correlated to degree of differentiation （P 〈0.05）, not correlated to patient age, tumor size, clinical stage and lymph node metastasis（P 〉0.05）. The expression of COX-2 was correlated to tumor size, degree of differentiation, clinical stage and lymph node metastasis （P 〈0.05）, not correlated to patient age （P 〉0.05）. Conclusion Topo U ct and COX-2 expression can be used as an indicator for predicting the differentiation, infiltration and metastasis characteristics of breast cancer.
出处
《肿瘤研究与临床》
CAS
2011年第2期100-102,共3页
Cancer Research and Clinic
基金
基金项目：广州市卫生局科研基金（2008-YB-238）
